Phys Written Answers · general-medicine
Undifferentiated Back Pain — Written Clinical Reasoning
DCE long-case preparation: structured written reasoning for the patient with undifferentiated back pain, covering the triage framework (mechanical, radicular, red-flag serious pathology), the complete differential (mechanical, inflammatory, infective, malignant, metabolic, referred), the NICE NG59 red flags and cauda equina syndrome, the focused history and the systematic spine and neurological examination (straight leg raise, femoral stretch test, per rectal), the targeted investigations, and the integration of competing diagnoses in the complex multimorbid patient.
On this page & tools
Target exams
SAQ 1 — Integrated Diagnostic Approach to Inflammatory Back Pain (20 marks, 30 minutes)
Prompt: Outline your integrated diagnostic approach to Mr Tran's presentation, addressing: (a) the triage framework and the prioritised differential; (b) the clinical features that discriminate inflammatory from mechanical back pain and the ASAS classification criteria for axial spondyloarthritis; (c) the role of the HLA-B27, the X-ray and the MRI in the diagnostic work-up; (d) the extra-articular associations and the surveillance you would undertake; (e) the pharmacological management, including the first-line therapy and the escalation pathway; and (f) the common exam trap in this patient. [1]
Model Answer
(a) Triage framework and prioritised differential (3 marks): [1]
The triage framework sorts every back pain patient into non-specific (mechanical) back pain, radicular (nerve root) pain, or back pain with red flags (serious pathology) [1]. Mr Tran does not fit the mechanical bin (his pain improves with exercise, not with rest; he has morning stiffness over an hour), he does not have radicular pain (no dermatomal radiation, no neurological deficit), and he does not have the infective or malignant red flags (no fever, no weight loss, no night sweats, no progressive unremitting pain). He does, however, have the classic inflammatory back pain criteria, with the extra-articular features of psoriasis and uveitis. The prioritised differential is therefore: first, axial spondyloarthritis (ankylosing spondylitis), strongly supported by the clinical picture, the raised inflammatory markers, the HLA-B27 and the bilateral sacroiliitis; second, the spondyloarthritis associated with psoriasis or inflammatory bowel disease (to be screened for); third, a mechanical contributor (possible, but not the primary driver).
(b) Discrimination of inflammatory from mechanical back pain and the ASAS criteria (4 marks): [1]
The ASAS inflammatory back pain criteria are my framework, and Mr Tran meets at least four of the five: age of onset under 40 (he is 34), insidious onset, improvement with exercise, no improvement with rest, and night pain improving on rising. He also has morning stiffness over an hour, which is the inflammatory signature. The discriminating features from mechanical pain are the opposite response to activity (inflammatory improves, mechanical worsens), the night pain that improves on rising (mechanical pain is typically relieved by lying down), and the morning stiffness over 30 minutes. Four out of five of these criteria have a sensitivity of over 70 per cent and a specificity of over 80 per cent for axial SpA [6].
The ASAS classification criteria for axial spondyloarthritis apply to the patient with chronic back pain (over 3 months) and onset under 45 years. There are two arms: the imaging arm (sacroiliitis on imaging — radiography or MRI — plus at least one SpA feature) and the clinical arm (HLA-B27 positive plus at least two SpA features). Mr Tran meets the imaging arm — he has bilateral grade 2 sacroiliitis on the pelvic X-ray (the imaging) plus psoriasis (the SpA feature). The SpA features include inflammatory back pain, arthritis, enthesitis (heel), uveitis, dactylitis, psoriasis, Crohn disease or ulcerative colitis, a good response to NSAIDs, a family history of SpA, and an elevated CRP [6].
(c) The role of the HLA-B27, the X-ray and the MRI (3 marks): [1]
The HLA-B27 is neither necessary nor sufficient for the diagnosis. It is present in about 90 per cent of patients with ankylosing spondylitis but also in about 8 per cent of the general population, most of whom never develop the disease. Mr Tran's positive HLA-B27 is supportive but not diagnostic; he already meets the ASAS imaging arm, so the HLA-B27 is confirmatory. A negative HLA-B27 would not have excluded the diagnosis. [1]
The pelvic X-ray confirms the structural sacroiliitis — the bilateral grade 2 change — which is sufficient for the modified New York criteria for ankylosing spondylitis. The limitation of the X-ray is that the radiographic sacroiliitis takes years to develop, which is the source of the average 6 to 10 year diagnostic delay. [1]
The MRI of the sacroiliac joints is the modality that detects the early active inflammation (the bone marrow oedema) before the radiographic change, and it is the investigation that closes the diagnostic delay in the patient with the clinical picture but the normal X-ray. In Mr Tran, the MRI is not needed to make the diagnosis (the X-ray and the clinical picture are sufficient), but I would arrange it to assess the degree of active inflammation, which guides the escalation to a biologic. [1]
(d) The extra-articular associations and the surveillance (4 marks): [1]
Axial spondyloarthritis is a systemic disease, not just a back pain, and the surveillance spans multiple systems. The anterior uveitis (the commonest extra-articular feature, in about a third of patients) — I ask about eye pain, redness and photophobia, and I link him to ophthalmology for the early treatment of recurrence. The cardiovascular associations (aortic regurgitation from aortic root dilatation, and the conduction disease) — I arrange a baseline echocardiogram and an ECG. The pulmonary associations (apical pulmonary fibrosis and the restrictive chest wall disease from the costovertebral rigidity) — I monitor the chest expansion and the spirometry; his chest expansion is already reduced at 4 cm. The osteoporosis (the inflammation and the immobility increase the fracture risk) — I monitor the bone density. The inflammatory bowel disease — I ask about the chronic diarrhoea, the abdominal pain and the rectal bleeding, and I screen if any of these are present [6].
(e) The pharmacological management and the escalation pathway (4 marks): [1]
The first-line pharmacological therapy is a full-dose NSAID at the maximum tolerated dose for at least two to four weeks — naproxen 500 mg twice daily, or celecoxib 200 mg twice daily, with gastroprotection (a proton pump inhibitor) for the at-risk patient. The response to NSAIDs is itself a SpA feature in the classification criteria, and about half to two-thirds of patients respond adequately [6].
If the NSAID is insufficient, or if there are contraindications (renal impairment, peptic ulcer, cardiovascular disease), or if the disease is high-activity (a raised CRP, the active sacroiliitis on the MRI, the reduced function), I escalate to a biologic under rheumatology guidance — a tumour necrosis factor inhibitor (adalimumab 40 mg subcutaneously every two weeks, etanercept 50 mg weekly, or infliximab) or an interleukin-17 inhibitor (secukinumab), guided by the NICE NG65 and the international treat-to-target recommendations. I avoid the systemic corticosteroid for the axial disease (it is largely ineffective) and I reserve the intra-articular corticosteroid for the peripheral joint or the sacroiliac joint injection in selected cases. The non-pharmacological management — the structured physiotherapy, the daily spinal mobility and postural exercise, and the smoking cessation — is the other cornerstone [6].
(f) The common exam trap (2 marks): [1]
The trap is the diagnostic delay — the registrar who attributes the insidious-onset back pain of a young man with psoriasis and uveitis to a "lumbar strain" or a "muscular pain" and does not ask the inflammatory back pain criteria questions, misses the diagnosis for years, during which the untreated inflammation causes the irreversible structural damage and the spinal rigidity. The corollary is that the registrar who asks the inflammatory back pain criteria, examines for the extra-articular features (the skin, the eyes, the entheses), and measures the modified Schober and the chest expansion has made the diagnosis that day [6]. The second trap is treating the back pain with an opioid or an epidural injection without addressing the underlying inflammation — the symptom is suppressed but the disease progresses.
SAQ 2 — The Diagnostic Pathway for the Patient with Back Pain and Red Flags (10 marks)
Prompt: A junior doctor asks you to explain: (a) the NICE NG59 red flags for back pain and the pathology each red flag suggests; (b) the clinical features of cauda equina syndrome and the emergency management; and (c) the synthesis you would give a colleague who is considering an MRI for every patient with acute non-specific back pain. [1]
Model Answer
(a) The NICE NG59 red flags (4 marks): [1]
The red flags are the screen that sorts the patient into the "serious pathology" bin and drives the investigation. Grouped by the pathology they suggest [2][3]: cauda equina or cord compromise — saddle anaesthesia, urinary retention or incontinence, faecal incontinence, bilateral or severe leg symptoms, a sensory level, a progressive neurological deficit; fracture — age of onset under 20 or over 50, sudden severe trauma, a history of osteoporosis or chronic corticosteroid use; infection — fever, recent bacterial infection, intravenous drug use, immunocompromise; malignancy — a history of cancer, weight loss, night pain, constant progressive non-mechanical pain, age over 50; inflammation — age of onset under 20, morning stiffness over 30 minutes, improvement with exercise, alternating buttock pain, the extra-articular features of SpA; and other — thoracic pain (an uncommon site of mechanical pain, think malignancy and infection), structural deformity, and the systemically unwell patient.
(b) The clinical features and the emergency management of cauda equina syndrome (3 marks): [1]
Cauda equina syndrome is the compression of the lumbosacral nerve roots below the conus, and the features are: severe low back pain (often bilateral), bilateral sciatica (or a change in the pattern of an existing sciatica), saddle anaesthesia (numbness in the perianal, perineal and genital regions — the S2 to S4 dermatomes), urinary retention or incontinence (painless retention is the classic sign; a post-void residual on the bladder scan is more sensitive than the history), faecal incontinence or loss of the sensation of rectal fullness, reduced anal tone on the per rectal examination, and a lower limb motor deficit (often bilateral). The classic complete triad is often absent at presentation, which is why the diagnosis is made by a high index of suspicion and the objective findings [4].
The emergency management is an MRI within 24 hours and the urgent surgical decompression, ideally within 24 to 48 hours of the onset of the deficit. The prognosis for the recovery of the bladder and the bowel function is better the earlier the decompression, and it is the sphincter function that recovers least well [4]. The threshold to image must be low — the registrar who suspects cauda equina performs the per rectal examination and the bladder scan, and if either is abnormal, arranges the emergency MRI.
(c) The synthesis on the overuse of MRI in non-specific back pain (3 marks): [1]
The synthesis I would give the colleague is that the routine MRI in acute non-specific back pain, in the absence of red flags, is low-value care. The evidence, from the foundational review by Deyo and Weinstein onward, is unambiguous: the imaging does not improve the outcomes; it reveals the age-related abnormalities (disc bulges, degenerative change) that are present in asymptomatic people; and it drives a cascade of low-value downstream care — the referrals, the injections, the surgery — that does not improve the outcome and that carries its own harms [1]. The NICE NG59 guideline, the American College of Physicians 2017 guideline and the 2018 Lancet Low Back Pain Series all converge on this point [2][3]. The corollary is that the red flag screen is the safeguard — the registrar who screens every back pain patient for the red flags, and who images only the minority who have them, has practised the evidence-based medicine. The Choosing Wisely principle — endorsed by the Australian Rheumatology Association, the American College of Physicians and the American College of Radiology — is explicit: imaging for non-specific back pain within the first 6 weeks, in the absence of red flags, should not be routine.
References
- [1]Deyo RA, Weinstein JN Low back pain N Engl J Med, 2001.PMID 11172169
- [2]Chou R, Deyo R, Friedly J, et al. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians Ann Intern Med, 2017.PMID 28192789
- [3]Foster NE, Anema JR, Cherkin D, et al.; Lancet Low Back Pain Series Working Group Prevention and treatment of low back pain: evidence, challenges, and promising directions Lancet, 2018.PMID 29573872
- [4]Lavy C, James A, Wilson-MacDonald J, Fairbank J Cauda equina syndrome BMJ, 2009.PMID 19336488
- [5]Mylona E, Samarkos M, Kakalou E, Fanourgiakis P, Skoutelis A Pyogenic vertebral osteomyelitis: a systematic review of clinical characteristics Semin Arthritis Rheum, 2009.PMID 18550153
- [6]Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection Ann Rheum Dis, 2009.PMID 19297344